How does a patient who is PNPLA-3 positive (heterozygote or homozygote) impact how you formulate their therapeutic plan?

At this time, the PNPLA3 positive status (heterozygote or homozygote) does not impact my formulation of a therapeutic plan, as my decisions to treat (and how to treat) are based on underlying MASLD disease activity and severity. My treatment decisions are tailored to patients' underlying risk factor...

In my current practice, I am not impacted by this status. However, in patients who are homozygous, I would counsel the patient on the potential for more pronounced disease acceleration. I do not routinely check this in my practice either.